Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment
I'm PortAI, I can summarize articles.
Labcorp Holdings Inc. has introduced Labcorp Plasma Detect™, a blood-based assay for detecting molecular residual disease (MRD) from circulating tumor DNA (ctDNA). Featured in Nature Medicine and Clinical Cancer Research, the assay has shown potential in tracking disease progression and improving post-surgical monitoring in cancer care. It may inform treatment strategies, particularly in diffuse pleural mesothelioma and head and neck cancer cases. The original content was published by Labcorp via PR Newswire on November 19, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments